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Summary Background Integrin signaling is an attractive tar-
get for anti-cancer treatment. GLPG0187 is a broad spectrum
integrin receptor antagonist (IRA). GLPG0187 inhibited tu-
mor growth and metastasis in mouse models. Methods We
aimed to determine the Recommended Phase II Dose
(RP2D) and to assess safety and tolerability of continuous i.
v. infusion in patients with advanced malignant solid tumors.
Anticipated dose levels were 20, 40, 80, 160, 320, and
400 mg/day in a modified 3 + 3 design. Plasma concentrations
of GLPG0187 were assessed to characterize the pharmacoki-
netics (PK). C-terminal telopeptide of type I collagen (CTX)
was used as pharmacodynamics marker. Results Twenty
patients received GLPG0187. No dose limiting toxicities
(DLTs) were observed. The highest possible and tested dose
was 400 mg/day. Fatigue was the most frequently reported
side effect (25 %). Recurrent Port-A-Cath-related infections
and skin toxicity suggest cutaneous integrin inhibition. No
dose-dependent toxicity could be established. PK analysis
showed a short average distribution (0.16 h) and elimination
(3.8 h) half-life. Continuous infusion resulted in dose propor-
tional PK profiles. We observed decreases in serum CTX
levels independent of the dose given, suggesting target en-
gagement at the lowest dose level tested. Single agent treat-
ment did not result in tumor responses. Conclusions
GLPG0187 was well tolerated with a dose-proportional PK
profile upon continuous infusion. No formal maximal tolerat-
ed dose could be established. GLPG0187 showed signs of
target engagement with a favourable toxicity profile. Howev-
er, continuous infusion of GLPG0187 failed to show signs of
monotherapy efficacy.
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Introduction
Integrin signaling plays an important role in cancer biology
providing a strong rationale to pursue integrin receptor antag-
onists (IRA) as therapeutic agents in cancer patients [1, 2].
Integrin receptors are heterodimeric cell surface molecules
that act as adhesion molecules connecting the cytoskeleton
to the extracellular matrix. Moreover they are involved in
activating intracellular signaling pathways, actin cytoskeleton
remodelling, three-dimensional cell growth and metastatatic
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organotropism [3, 4]. Integrin-mediated signaling is implicat-
ed in modulation of well-known cancer-related pathways such
as the TGF-beta pathway in glioblastoma and the Rho-Rac
pathway [2, 5, 6].
Cilengitide is the most advanced IRA in clinical develop-
ment. Cilengitide showed signs of efficacy without significant
additive toxicity both as single agent and combined with ra-
diation and temozolomide in patients with glioblastoma
multiforme (GBM) [7–9]. Unfortunately cilengitide failed to
live up to its promise in a phase III clinical trial when com-
bined with standard treatment in GBM and further clinical
development seems unlikely [10–12]. When compared to
cilengitide, GLPG0187 has a stronger nanomolar affinity for
a broader panel of RGD (Arg-Gly-Asp) integrin receptors
(αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1; supplementary
table S1 and [13, 14]). In preclinical models GLPG0187 sig-
nificantly inhibited angiogenesis both in vivo and in vitro,
osteoclastogenesis in vitro, and bone loss in vivo [15]. In
mouse cancer models GLPG0187 inhibited de novo formation
and progression of bone and visceral metastases in prostate
cancer and breast cancer [13, 14, 16, 17]. We hypothesized
that GLPG0187, a more potent and broader spectrum IRA
when compared to cilengitide, may improve the anti-tumor
efficacy of IRA therapy. Therefore a phase I dose escalation
study was initiated to investigate the safety and tolerability of
GLPG0187 when administered intravenously in end-stage
cancer patients. In healthy volunteers, GLPG0187 was rapidly
eliminated after oral administration with a terminal half-life of
about 5–6 h [18]. To ensure continuous target inhibition de-
spite its relatively short half-life GLPG0187 was administered
as a continuous i.v. infusion in this study. We aimed to deter-
mine a safe dose in cancer patients and to determine the phar-
macokinetics (PK), pharmacodynamics (PD) and evaluate
preliminary signs of efficacy.
Materials and methods
Patient selection
Patients, aged over 18 years, with pathologically confirmed
advanced or metastatic malignant solid tumors refractory to
standard therapy or for whom no standard treatment options
were available were eligible for participation. Additional in-
clusion criteria included: written informed consent, measur-
able disease according the Response Evaluation Criteria In
Solid Tumors (RECIST) version 1.1 [19], Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0–2,
estimated life expectancy of at least 12 weeks and no previ-
ously incurred anticancer therapy related toxicities higher than
grade 2. Patients were considered ineligible if there was less
than 4 weeks since their last anticancer therapy (less than
6 weeks for nitrosoureas and mitomycin C) or they were
previously treated with IRAs. Additional exclusion criteria
were: chronic treatment with corticosteroids equivalent to
10 mg methylprednisolone per day or more, current or recent
(within 30 days) treatment with another investigational drug
or participation in another investigational study, clinically
symptomatic or progressive brain or leptomeningeal metasta-
ses, major surgical procedure within 28 days before first dose,
congestive heart failure (NYHA class 3 or 4), clinical signif-
icant cardiac arrhythmias, signs and symptoms of relevant
cardiovascular disease, known hypersensitivity to any of the
study drugs and significant medical conditions possibly inter-
fering with patient compliance or safe study participation.
Female patients with reproductive potential were only eli-
gible with a negative pregnancy test obtained less than 7 days
before first dose and if an adequate contraceptive method was
used while on study. There were no restrictions in concomitant
medication.
The study was centrally approved by the ethics committee
of the University Medical Center Utrecht and was conducted
according to the Declaration of Helsinki and Good Clinical
Practice guidelines. Written informed consent was obtained
from all patients. The study was registered on clinicaltrials.
gov (NCT01313598).
Investigational agent
GLPG0187 supply was controlled by Galapagos SASU
(Romainville, France) and was delivered to participating sites
as a 35 mg/ml injectable solution in type 1 clear glass vials. A
40 % HP-β-CD (Kleptose®) injectable solution manufactured
by Roquette pharma (Lestrem, France) was used to improve
solubility of GLPG0187. Depending on dose level, various
amounts of GLPG0187were dissolved in HP-β-CD injectable
solution and saline and administered by continuous infusion to
patients at the recommended infusion rate. The amount of
HP-β-CD needed to prepare a 400 mg/day GLPG0187 solu-
tion (around 8 g/day) was considered the maximum accept-
able dose in humans based on the clinical experience with
itraconazole solved in HP-β-CD. No dose escalation beyond
400 mg/day was planned within this study. After preparation,
the solution was stored at room temperature protected from
daylight for a maximum of 7 days.
Study design
This study was performed as a multicenter, open-label,
dose-escalation, phase I study. Patients were accrued in the
University Medical Center Utrecht and The Netherlands Can-
cer Institute. Decisions regarding dose escalation were made
by using a modified 3 + 3 dose escalation design. To reduce
the number of patients treated at possible suboptimal dose
concentrations, only 2 evaluable patients were assigned in
the first two cohorts.
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A small wearable infusion pump (Pega plus infusion pump,
Venner Medical, Ecublens,
Switzerland) enabled continuous GLPG0187 infusion at
home through a Port-A-Cath (PAC) or peripherally inserted cen-
tral catheter (PICC). Renewals of the infusion pumps and bags
were performed at weekly hospital visits with at the higher dose
levels additional renewals at home by specialized nurses. With
these measures continuous infusion was possible with as little as
possible impact on participants daily lives and wellbeing.
Patients in the first cohort received a starting dose of
20 mg/day which was chosen based on results from a preced-
ing healthy volunteer study [18]. The anticipated sequential
dose escalations were 20, 40, 80, 160, 320 and 400 mg/day.
Intrapatient dose-escalations were not allowed. Dose reduc-
tions or interruptions were allowed after cycle 1 which equals
the dose limiting toxicity (DLT) window.
On day 1 of cycle 1, a single daily dose of GLPG0187 was
administered at a constant infusion rate for a period of 1 hour
after which the patient was followed for 24-h to assess the PK
profile. On day 8 of cycle 1 continuous infusion was initiated at
the assigned dose level for 21 days. Thereafter, treatment was
continued uninterrupted in 21-day cycles until disease progres-
sion, occurrence of a DLT, unacceptable toxicity, death, poor
study compliance or withdrawal of informed consent.
A DLT was defined as one of the following adverse events
(AEs) considered related to GLPG0187 occurring within the
first cycle of 28 days: grade 4 neutropenia lasting ≥7 consecutive
days, febrile neutropenia (defined as absolute neutrophil count
(ANC) ≤ 1000 cells per μL and fever ≥38.5 °C) or documented
infection ≥ grade 3 with ANC ≤ 1000 cells/μL, grade 4 throm-
bocytopenia, thrombocytopenia requiring platelet transfusion, or
bleeding requiring medical intervention, alanine aminotransfer-
ase (ALT) or aspartate aminotransferase (AST) > 5 × upper limit
of normal (ULN) (> 7.5 × ULN in case of liver metastases) for
greater than 14 days, ALT or AST > 5 × ULN (> 7.5 × ULN in
case of liver metastases) co-occurring with a total bilirubin of
>2.5 × ULN (not explained by obstruction) regardless of dura-
tion, non-hematological toxicity ≥ grade 3. GLPG0187-related
nausea, vomiting, and diarrhoea were only considered DLTs if
they persisted at ≥ grade 3 for >3 days despite adequate support-
ive care measures.
The Maximum Tolerated Dose (MTD) for this study was
defined as the dose level below the dose level at which ≥2
patients in a dose cohort experienced a DLT within the DLT
observation period. The resulting recommended phase II dose
(RP2D) was defined as the MTD or the highest tested dose
which is tolerable and safe.
Safety and efficacy assessments
After signing informed consent, patients were screened for
eligibility. Screening assessments were performed within
14 days of the first dose.
Safety was assessed weekly by means of physical exami-
nation, weight, vital signs, ECOG performance status, labora-
tory evaluations (hematology, biochemistry and urinalysis),
electrocardiograms, and recording of concurrent illness/
therapy and AEs throughout the study course. An AE was
defined as appearance of any (or worsening of any
preexisting) undesirable sign, symptom or medical condition
occurring after signing the informed consent, whether related
to treatment or not. Toxicity was graded according to the Na-
tional Cancer Institute Common Terminology Criteria for Ad-
verse Events (NCI-CTCAE) version 4.03. For each AE an
absent, unlikely, possible, probable or certain relationship
with GLPG0187 was assessed by the local investigator.
Preliminary efficacy was measured bi-cyclic and at end of
treatment by CTscan, MRI, or a bone scan following RECIST
1.1 [19]. Recent literature has highlighted the need for better
criteria for response assessment in high-grade gliomas, and the
Response Assessment in Neuro-oncology (RANO) group has
published new MRI-based response criteria [20]. For this rea-
son, we evaluated all high-grade glioma patients according to
RANO criteria. Concordance between RANO and RECIST
evaluation of all gliomas was 100 %.
Pharmacokinetic and pharmacodynamic methods
PK blood samples were collected at baseline and on day 1 of
cycle 1 at 0.5, 1, 1.5, 2, 4, 6, 8 and 24 h after start of the single
first dose. Additional samples were obtained on day 8, 15, 22
and 28 of cycle 1. PK samples were analyzed for determina-
tion of GLPG0187 plasma levels by a validated liquid
chromatography-mass spectrometry methods at AtlanBio
(Saint-Nazaire, France). PK parameters in plasma such as
maximum concentration (Cmax), Area Under the Curve
(AUC), total plasma clearance, steady state volume of distri-
bution (Vss) and distribution and elimination half-lives (t1/2lbd1
and t1/2lbdz) were calculated, as well as dose standardized pa-
rameters (Cmax/dose and AUC/dose).
Integrin signaling is crucial for bone resorption by osteo-
clasts [21, 22]. In a study performed by van der Horst et al.
GLPG0187 inhibited osteoclastic bone resorption in mice sig-
nificantly [15]. In addition, GLPG0187 was shown to signif-
icantly reduce CTX (C-terminal telopeptide of type I collagen)
levels when compared with placebo in a phase I healthy vol-
unteer study [18]. Therefore CTX, a well-established marker
for bone turn-over, was adopted as surrogate PDmarker in this
study [23]. CTX serum levels were measured by ELISA, ac-
cording to the manufacturer instructions (CrossLaps, Immuno
Diagnostic Systems, ref. AC-02F1).
CTX levels were measured in blood samples collected at
baseline and on day 1 of cycle 1 at 1, 2, 4, 6, 8 and 24 h after
start of the first single dose. Additional samples were obtained
on day 8, 15, 22 and 28 of cycle 1. These samples were
obtained in the morning in a fasting state.
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Statistical methods
Study results were obtained by analyzing the safety popula-
tion which contains all patients who received at least 1 dose of
GLPG0187. Results were summarized descriptively and if
applicable plotted by dose level over time. CTX levels at




Twenty patients received GLPG0187, between 22nd of
March 2011 and 10th of April 2013. Patient characteristics
are depicted in Table 1. Fifteen patients completed cycle 1
and were considered evaluable for DLT assessment. Patients
with progressive high-grade glioma were most commonly in-
cluded (40 %, GBMs) based on pre-clinical and early phase
clinical data available [24, 7, 25].
Dose escalation and safety
No DLTs were observed in any cohort. The absence of DLTs
resulted in an undisturbed dose escalation scheme towards the
final planned cohort of 400 mg/day. No MTD could be
established.
GLPG0187 showed a tolerable toxicity profile in this
study. The incidence of at least possibly related AEs per co-
hort is summarized in Table 2. Most frequently observed tox-
icities were fatigue (5 patients, 25 %) and skin related adverse
events (5 patients, 25 %). Twenty-three AEs were considered
possibly related and 6 probably related to GLPG0187. All but
two AEs are reported only once. During the study, 14 (70 %)
patients experienced a total of 23 serious adverse events
(SAE). Only one SAE was considered possibly related (fa-
tigue). All other SAEs were assessed as unlikely or
not-related.
All toxicity seemed manageable and did not lead to dose
reductions or dose interruptions. No clear relationship was
observed between GLPG0187 dose level and the occurrence
of AEs or laboratory abnormalities.
Pharmacokinetic data
After intravenous infusion, GLPG0187 was rapidly distribut-
ed and eliminated as illustrated in Fig. 1a. The PK profile was
dose proportional over the 20 to 400 mg/day dose range when
infused continuously (Fig. 1b). PK parameters per cohort are
displayed in Table 3. GLPG0187 showed a moderate total
plasma clearance (average: 40.1 L/h) and short distribution
and elimination half-lives of on average 0.16 and 3.8 h,
respectively. GLPG0187 plasma concentration was main-
tained during the PK sampling period of 21 days while receiv-
ing continuous i.v. infusion (Fig. 1b).
Effects on bone resorption marker CTX
The effect of GLPG0187 treatment on CTX levels was
measured in serum during the first cycle and is depicted
in Fig. 2a/b. High intra- and interpatient variability in the
CTX concentration measurements was observed. The
presence of bone metastases in 3 patients was not explan-
atory for the variability observed. A Wilcoxon Signed
Rank Test was conducted to compare CTX levels of the
total study population at baseline to 2 h post infusion on
cycle 1 day 1. Additionally, the effect of continuous infu-
sion was analyzed by comparing mean CTX levels at day
Table 1 Patient demographics



















Glioblastoma multiforme 5 (25)
Anaplastic oligodendroglioma 2 (10)
High grade astrocytomaa 1 (5)
Colorectal carcinoma 3 (15)
Adenocarcinoma of Unknown Primary 1 (5)
Adenoid cystic carcinoma 1 (5)
Cholangiocarcinoma 1 (5)
Endometrial cancer 1 (5)
Nasopharynxcarcinoma 1 (5)
Non-small cell lung cancer 1 (5)
Ocular Melanoma 1 (5)
Osteosarcoma 1 (5)
Urothelial cell carcinoma 1 (5)
N number of patients, ECOG Eastern Cooperative Oncology Group per-
formance status
a Secondary form, from low grade astrocytoma
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15 to day 8. A significant change in CTX level was ob-
served 2 h after the single dose infusion on day 1. The
mean CTX level of the total study population was higher
at baseline: 0.58 ng/ml (SD 0.39) versus 0.42 ng/ml (SD
0.32), p < 0.0001. At day 15 CTX levels were lower
compared to day 8 (p = 0.007). No relationship between
GLPG0187 dose and change in CTX concentration was
observed within cycle 1.
Efficacy
Stable disease was observed in 3 (15 %) out of 20 pa-
tients. These 3 patients were treated at 20 mg/day (patient
with non-small cell lung cancer, stable disease during
14 weeks), 80 mg/day (patient with GBM, stable disease
during 19 weeks) and 160 mg/day (patient with GBM,
stable disease during 8 weeks). No tumor responses were
observed.
Discussion
We performed a phase I, open-label, dose escalation study
using GLPG0187 in patients with solid tumors. GLPG0187
was well-tolerated and displayed a predictable and dose pro-
portional PK profile. The toxicity profile of GLPG0187 when
given as a continuous iv infusion is mild at the maximal ad-
ministered dose and we did not identify a maximal tolerated
dose.
Although no directly related severe toxicity was observed
we did observe PAC related infections in three out of six
patients in the first two cohorts. They received GLPG0187
through a PAC system. As the median reported infection rate
of totally implantable intravenous catheter devices within an
immunosuppressed population approximates 0.2 per 1000
catheter days [26] we consider these events retrospectively
as possibly related to GLPG0187. For all three patients the
infection was evident at the skin location where the needle
Table 2 All and ≥ Grade 3 at least possibly GLPG0187-related AEs per dose cohort
20 mg/day 40 mg/day 80 mg/day 160 mg/day 320 mg/day 400 mg/day Total
(N = 2) (N = 5) (N = 4) (N = 3) (N = 3) (N = 3) (N = 20)
Adverse event descriptiona All ≥Gr 3 All ≥Gr 3 All ≥Gr 3 All ≥Gr 3 All ≥Gr 3 All ≥Gr 3 All ≥Gr 3
Dry mouth 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Epidermolysis 0 0 0 0 1 0 0 0 0 0 0 0 1 0
Fungal skin infection 0 0 0 0 0 0 0 0 1 0 0 0 1 0
Herpes zoster 0 0 0 0 1 0 0 0 0 0 0 0 1 0
Mucosal inflammation 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Rash 0 0 1 0 0 0 0 0 0 0 0 0 1 0
Rash Maculo-papular 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Skin hyperpigmentation 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Arthralgia 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Conjunctival Haemorrhage 0 0 0 0 0 0 0 0 0 0 1 0 1 0
Diarrhoea 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Dysgeusia 0 0 0 0 0 0 0 0 0 0 1 0 1 0
Fatigue 0 0 0 0 2 0 1 0 1 1 1 0 5 1
Headache 0 0 0 0 1 0 0 0 0 0 0 0 1 0
Oedema peripheral 0 0 0 0 0 0 0 0 1 0 0 0 1 0
Peripheral sensory neuropathy 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Pleural effusion 0 0 0 0 0 0 0 0 1 0 0 0 1 0
Thrombosis 0 0 0 0 1 0 0 0 0 0 0 0 1 0
Vasculitis 0 0 1 0 0 0 0 0 0 0 0 0 1 0
ALT increased 0 0 0 0 1 1 0 0 0 0 0 0 1 1
Anemia 0 0 1 0 0 0 0 0 0 0 0 0 1 0
Blood albumin decreased 0 0 2 0 0 0 0 0 0 0 0 0 2 0
Blood bilirubin increased 0 0 1 0 0 0 0 0 0 0 0 0 1 0
Blood creatinine increased 0 0 1 0 0 0 0 0 0 0 0 0 1 0
Total 7 0 7 0 7 1 1 0 4 1 3 0 29 2
ALTAlanine aminotransferase, N number of patients
a Adverse events were evaluated using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.03
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enters the skin. From cohort 3 onwards we switched to a
PICC, where access to the system does not require repeated
skin punctures. No catheter related infections were observed
after the switch from PAC to PICC. These observations com-
bined with the fact that skin toxicity was the most common
side effect found suggest that skin integrity may be compro-
mised in the presence of GLPG0187. The observed changes in
CTX levels indirectly suggest that GLPG0187 does inhibit
integrin function. Despite the baseline variation we found a
statistically significant decrease in CTX levels after
GLPG0187 administration. Bone turnover, and associated
markers including CTX, follow a circadian rhythm with peak
levels at night and a decrease towards nadir in the afternoon
[27, 28]. All patients received their single dose on day 1 in the
Fig. 1 a The graph depicts the
mean plasma concentration of
GLPG0187 over the first 6 h after
GLPG0187 treatment start.
GLPG0187 concentration
observed at 8 and 24 h post-
infusion was below the limit of
quantification. b The graph
depicts the mean plasma
concentration of GLPG0187 over
14 days during continuous
GLPG0187 i.v. infusion. Plasma
concentrations on day 8 were
below the level of quantification













AUC (0-inf) (ng.h/mL) 422 1689 (822) 1866 (387) 4357 (1764) 12,386 (3951) 10,114 (6693)
AUC (0-inf)/dose (ng.h/mL) 21.1 47.3 (18.4) 23.3 (4.8) 27.2 (11.0) 38.7 (12.3) 25.3 (16.7)
t1/2,lbd1 (h) 0.182 0.180 (0.097) 0.117 (0.045) 0.165 (0.060) 0.148 (0.022) 0.140 (0.030)
t1/2,lbdz (h) 2.41 2.98 (1.01) 3.92 (1.27) 4.68 (0.35) 5.07 (0.26) 3.44 (1.11)
Cmax (ng/mL) 391 1460 (677) 1751 (396) 3969 (1511) 11,490 (3821) 9592 (6340)
Cmax/dose (ng/mL.mg) 19.5 41.1 (15.5) 21.9 (5.0) 24.8 (9.4) 35.9 (11.9) 24.0 (15.9)
CL (L/h) 48.7 24.3 (10.3) 44.3 (9.2) 42.5 (21.6) 27.6 (8.2) 53.2 (33.3)
Vss (L) 25.6 15.4 (13.0) 25.7 (17.3) 26.1 (2.2) 20.6 (7.1) 23.0 (14.5)
N number of patients, AUC area under the curve, t1/2,lbd1 distribution half- life, t1/2,lbdz terminal elimination half- life, Cmax maximum concentration, CL
clearance, Vss steady state volume of distribution
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morning. Therefore, on day 1 we cannot exclude the possibil-
ity that CTX levels in our patients partially, if not completely,
decreased by a physiological phenomenon rather than a PD
effect. However, the clear decrease at day 15 cannot be ex-
plained in this manner and most likely represents a treatment
effect. Thus, both toxicity and PD correlative markers suggest
a treatment dependent inhibition of physiological integrin
signaling.
During this study the development of cilengitide, the first
generation IRA stopped due to a negative trial in patients with
high-grade glioma [10, 11]. These disappointing results for
cilengitide may reflect either inherent inefficacy of cilengitide
or problems with dose, scheduling and patient selection. Re-
garding dose and scheduling it appears that more could be less
and intermittent scheduling could have more efficacy than
more intensive schedules [12]. Here we explored the extreme
of exposure driven therapy: continuous iv infusion. Although
continuous exposure seems to be important in treatment
targeting driving oncogenic pathways such as BRAF or EGFR
it is questionable whether integrin signaling could be
classified as such. Authors have proposed that inadequate ex-
posure may in part explain the lack of efficacy of cilengitide
[29]. Our data suggest that even continuous iv infusion of a
more potent IRA does not result in the expected efficacy
signals.
The development of IRAs in oncology has been largely
disappointing and our study suggests that the lack of efficacy
cannot easily be attributed to exposure, completeness of
integrin signaling blockade or affinity issues of the first gener-
ation compounds. Indeed the pre-clinical models have failed to
lead theway for rational drug design and rational trial design for
IRAs. The data known for cilengitide in the clinical setting
warrants a discontinuation of IRA development until novel
more relevant combination strategies have been designed that
can be tested in small proof-of-principle clinical trials.
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